A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Status:
RECRUITING
Trial end date:
2028-05-20
Target enrollment:
Participant gender:
Summary
This is a single - arm, multi - cohort, open - label, multi - center Phase II clinical study. It aims to evaluate the efficacy and safety of F182112 combined with different administration regimens in patients with relapsed or refractory multiple myeloma.